Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02435147 · ClinicalTrials.gov registry record

Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index

A clinical trial of Osteoporosis and Bone Fracture, sponsored by HealthEast Care System.

Completed
Registry status
86
Enrollment target
1
Study location

NCT02435147: Completed study of Osteoporosis and Bone Fracture, sponsored by HealthEast Care System.

NCT02435147 is a study of Osteoporosis and Bone Fracture that has completed, run by HealthEast Care System. The registered enrollment target is 86 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02435147, a study of Osteoporosis and Bone Fracture, has completed, sponsored by HealthEast Care System.

COMPLETED
Registry status
86 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to validate the long-term benefit of denosumab for osteoporosis treatment in a real-world clinical practice setting. We hypothesize that continued therapy (36+months) with denosumab will increase both trabecular bone score (TBS) and femur strength index (FSI) and reduce fracture and other bone health risks among post-menopausal women with osteoporosis.

Primary Outcome

Proportion of change in mean trabecular bone score at 36 months following denosumab initiation

Interventions

  • DRUG denosumab

Study Locations (1)

Minnesota

  • HealthEast Care System - Saint Paul

Trial Details

FieldValue
Enrollment Target 86 participants
Start Date 2015-04
Est. Completion 2016-06
HealthEast Care System

5 total trials

What the finished NCT02435147 record still lists

NCT02435147 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Osteoporosis appearing as the primary indexed condition, and to 1 intervention - of which denosumab is the first listed.

NCT02435147 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT02435147 about?

NCT02435147 is a clinical study titled "Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index". The purpose of this study is to validate the long-term benefit of denosumab for osteoporosis treatment in a real-world clinical practice setting. We hypothesize that continued therapy (36+months) with denosumab will increase both trabecular bone score (TBS) and femur strength index (FSI) and reduce ...

What is the current status of trial NCT02435147?

This trial is currently completed. The enrollment target is 86 participants. The study started on 2015-04. Estimated completion is 2016-06.

What conditions does trial NCT02435147 study?

This clinical trial studies the following conditions: Osteoporosis, Bone Fracture.

What interventions are being tested in trial NCT02435147?

The interventions under investigation include: denosumab (DRUG).

Who is sponsoring clinical trial NCT02435147?

This trial is sponsored by HealthEast Care System, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02435147 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoporosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02435147's enrollment target sits among peer trials

86 42nd of 84 higher than 43 of 84 other Osteoporosis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01639508 · 86 participants · Phase 2

    Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

  • NCT03519269 · 86 participants · NA

    Navio Robotic Versus Conventional Total Knee Arthroplasty

  • NCT04132999 · 86 participants · NA

    PAP for Children With DS and OSAS

  • NCT04545957 · 86 participants · NA

    Jump: MR Simulation For Radiation Therapy Master Protocol

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02435147, the US trial registry maintained by the National Library of Medicine. NCT02435147 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.